Author Archives: admin

Dementia is a brain disorder that causes memory to become poor and seriously disturbs thinking ability to the point that it interferes with social and occupational functioning. There are many types of dementias, and there are multiple causes of dementia, including … Continue reading →

People with Down’s syndrome or trisomy 21 (a genetic disorder causing mental retardation in which there are 3 copies of chromosome 21 instead of the normal 2 copies) are at greater risk of developing a dementia that is like Alzheimer’s disease … Continue reading →

People with more years of education lose their memory faster than those with less education in the years prior to a diagnosis of dementia. Research shows that people with more education have more rapid memory loss after diagnosis of dementia. It … Continue reading →

One out of eight people age 65 and older (13%) has Alzheimer’s disease. Women, who on average live longer than men, are more likely than men to have Alzheimer’s disease. The greatest risk factor for Alzheimer’s disease is advancing age, but … Continue reading →

In April, 2010 the Journal of the American Geriatrics Society published online a Wake Forest study of nursing home residents who were taking medications for dementia – donepezil (Aricept), glantamine (Razdyne), rivatigmine (Exelon), and tacrine (Cognex) — as well as anticholingeric medications for incontinence. … Continue reading →

Results of a randomized trial show no beneficial effect of Ginkgo biloba in the prevention of Alzheimer’s disease or dementia in subjects with normal cognition or in those with mild cognitive impairment. This randomized, placebo-controlled clinical trial was carried out at … Continue reading →

Sundowning is defined as a period at the end of the day when a person with dementia exhibits more agitation or behavioral disturbances for NO known cause. Little research has been done in this area, but that which has been … Continue reading →

Experimental evidence has shown that patients with probable Alzheimer’s disease often have neuroinflammation and an increase  of inflammatory mediators. For this reason, various anti-inflammatory therapies have been investigated for their ability to decrease the risk of dementia. Epidemiologic studies have shown … Continue reading →

In a pilot study involving 95 people with mild to moderate Alzheimer’s dementia, reseachers randomly assigned people who were already receiving a stabilized dosage of the cholinesterase inhibitor, Razadyne (rivastigmine) to also receive Namenda (memantine) or placebo (a pill without any active ingredient) in a 12-week, open-label … Continue reading →